Cartesian Therapeutics has a strong cash position after a $130 million equity raise, extending its runway to support upcoming ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...

Analyst Thomas Smith of Leerink Partners maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report), retaining the price ...

An experimental mRNA cancer vaccine shows promising results in a Phase 1 trial, potentially offering new hope for ...

The technique is called in vivo CAR-M therapy. "The nomination of the two autoimmune targets is a significant milestone in ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to ...

Moderna (MRNA) plans to launch a skin cancer vaccine developed with Merck (MRK) in 2025, but faces stock pressure after ...

Modernas new cancer vaccine, mRNA-4359, shows promising results in early clinical trials. Utilizing mRNA technology, similar ...

Jim Cramer’s 10 Best Stock Picks for Investors Right Now. In this article, we are going to take a look at where Moderna, Inc.